Every material Form 8-K Allogene Therapeutics, Inc. has filed with the SEC since August 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Allogene Therapeutics reported a third-quarter 2026 net loss of $50.4 million, or $0.15 per share, up from a net loss of $41.4 million, or $0.19 per share, a year earlier. The company reported no collaboration revenue and said its cash, cash equivalents and investments of $388.9 million fund its operations into 2029, while its 2026 GAAP operating expense outlook is about $225 million.
Q3 2026 net loss was $50.4 million, or $0.15 per share, versus $41.4 million, or $0.19 per share, in Q3 2025
Research and development expenses were $41.9 million and general and administrative expenses were $12.9 million in Q3 2026
Cash, cash equivalents and investments were $388.9 million as of September 30, 2026; cash runway projected into 2029
2026 guidance: operating expense about $165 million; GAAP operating expenses about $225 million, including about $35 million of stock-based compensation
Allogene Therapeutics disclosed that Chief Financial Officer Geoffrey Parker gave notice on August 31, 2026 that he will retire from the company in all capacities, effective November 6, 2026. The filing does not name a successor or describe the reasons for the departure.
Geoffrey Parker, Executive Vice President and Chief Financial Officer and principal financial officer, provided notice of retirement on August 31, 2026
Retirement is effective November 6, 2026
The filing does not name a successor or interim financial officer
Allogene Therapeutics reported a second-quarter 2026 net loss of $42.7 million, or $0.13 per share, compared with $50.9 million, or $0.23 per share, a year earlier. The company also reported $423.6 million in cash, cash equivalents and investments as of June 30, 2026, and said that cash should fund operations into 2029. The filing furnishes a press release that also gives an update on its pivotal ALPHA3 trial of cema-cel in large B-cell lymphoma, including an interim MRD clearance result and FDA designations.
Second-quarter 2026 collaboration revenue from a related party was $4.6 million, versus none a year earlier.
Net loss was $42.7 million for the quarter ended June 30, 2026, versus $50.9 million in the same quarter of 2025.
Guidance: 2026 operating expense is expected to be about $165 million, and GAAP operating expenses about $225 million, excluding potential business development activity.
In the interim analysis, 58.3% (7/12) of cema-cel arm patients achieved MRD negativity versus 16.7% (2/12) in the observation arm; the FDA granted RMAT and Fast Track designations in July.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Allogene Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →